Medicine and HealthNature
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J. Zhang, Y. Hu, et al.
This groundbreaking research illustrates the creation of non-viral, gene-specific targeted CAR-T cells using CRISPR-Cas9, leading to an impressive 87.5% complete remission rate in patients with aggressive B-cell non-Hodgkin lymphoma. Conducted by a team of experts, the study highlights the innovative use of PD1 integration for enhanced anti-tumor efficacy.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Neutralizing IFNγ Improves Safety without Compromising Efficacy of CAR-T Cell Therapy in B-cell Malignancies
S. Manni, F. D. Bufalo, et al.
Medicine and Health
Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial
C. Moritz, E. C. Field-fote, et al.
Medicine and Health
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
D. Nixdorf, M. Sponheimer, et al.
Medicine and Health
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
